Carglumic acid for the treatment of N-acetylglutamate synthase deficiency and acute hyperammonemia

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 3, 2012, Pages 263-271

  Häberle, Johannes ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

carbamylglutamate; carglumic acid; hyperammonemia; isovaleric aciduria; methylmalonic aciduria; N acetylglutamate synthase deficiency; N carbamyl L glutamate; NAGS deficiency; organic acidurias; propionic aciduria

Indexed keywords

AMMONIA; CARGLUMIC ACID; GLUTAMINE; UREA;

ACIDURIA; AMMONIA BLOOD LEVEL; BITTER TASTE; CRYING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; ENZYME DEFICIENCY; FEVER; HUMAN; HYPERAMMONEMIA; MOLECULAR WEIGHT; N ACETYLGLURAMATE SYNTHASE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SWEATING; TACHYCARDIA; TREATMENT DURATION;

EID: 84862112615     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.17     Document Type: Review

References (73)

1. Bachmann C. Mechanisms of hyperammonemia. Clin. Chem. Lab. Med. 40 (7), 653-662 (2002). (Pubitemid 34982472)
2. Bachmann C. Inherited hyperammonemias. In: Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases. Blau N, Duran M, Blaskovic ME, Gibson KM (Eds.). Springer, Berlin, Germany, 261-276 (2003).
3. Häberle J. Clinical practice: the management of hyperammonemia. Eur. J. Pediatr. 170 (1), 21-34 (2011).
4. Häberle J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther. Clin. Risk Manag. 7, 327-332 (2011).
5. Bachmann C, Krähenbühl S, Colombo JP, Schubiger G, Jaggi KH, Tönz O. N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. N. Engl. J. Med. 304 (9), 543 (1981).
6. Caldovic L, Morizono H, Tuchman M. Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. Hum. Mutat. 28 (8), 754-759 (2007). (Pubitemid 47282436)
7. Brusilow S, Horwich A. Urea cycle enzymes. In: The Metabolic & Molecular Bases of Inherited Disease (8th Edition). Scriver C, Beaudet A, Sly W, Valle D (Eds). McGraw-Hill, NY, USA, 1909-1963 (2001).
8. Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into genetics, epidemiology, pathophysiology, and treatment. Appl. Clin. Genet. 4, 127-135 (2011).
9. Burlina AB, Bachmann C, Wermuth B et al. Partial N-acetylglutamate synthetase deficiency: a new case withuncontrollable movement disorders. J. Inherit. Metab. Dis. 15 (3), 395-398 (1992).
10. Caldovic L, Morizono H, Panglao MG, Cheng SF, Packman S, Tuchman M. Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia. Hum. Genet. 112 (4), 364-368 (2003). (Pubitemid 36869064)
11. Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann. Neurol. 52 (6), 845-849 (2002). (Pubitemid 35403198)
12. Heckmann M, Wermuth B, Häberle J, Koch HG, Gortner L, Kreuder JG. Misleading diagnosis of partialN-acetylglutamate synthase deficiency based on enzyme measurement corrected by mutation analysis. Acta Paediatr. 94 (1), 121-124 (2005). (Pubitemid 40127945)
13. Schubiger G, Bachmann C, Barben P, Colombo JP, Tönz O, Schüpbach D. N-acetylglutamate synthetase deficiency: diagnosis, management and follow-up of a rare disorder of ammonia detoxication. Eur. J. Pediatr. 150 (5), 353-356 (1991).
14. Häberle J, Denecke J, Schmidt E, Koch HG. Diagnosis of N-acetylglutamate synthase deficiency by use of cultured fibroblasts and avoidance of nonsensemediated mRNA decay. J. Inherit. Metab. Dis. 26 (6), 601-605 (2003). (Pubitemid 37321539)
15. Häberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat. Diagn. 24 (5), 378-383 (2004). (Pubitemid 38724865)
16. Nordenström A, Halldin M, Hallberg B, Alm J. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. J. Inherit. Metab. Dis. 30 (3), 400 (2007).
17. Elpeleg ON, Colombo JP, Amir N, Bachmann C, Hurvitz H. Late-onset form of partial N-acetylglutamate synthetase deficiency. Eur. J. Pediatr. 149 (9), 634-636 (1990). (Pubitemid 20211564)
18. Forget PP, van Oosterhout M, Bakker JA, Wermuth B, Vles JS, Spaapen LJ. Partial N-acetyl-glutamate synthetase deficiency masquerading as a valproic acid-induced Reye-like syndrome. Acta Paediatr. 88 (12), 1409-1411 (1999). (Pubitemid 30012569)
19. Caldovic L, Morizono H, Panglao MG et al. Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles. Hum. Mutat. 25 (3), 293-298 (2005). (Pubitemid 40365148)
20. Heibel SK, Ah Mew N, Caldovic L, Daikhin Y, Yudkoff M, Tuchman M. N-carbamylglutamate enhancement of ureagenesis leads to discovery of a novel deleterious mutation in a newly defined enhancer of the NAGS gene and to effective therapy. Hum. Mutat. 32 (10), 1153-1160 (2011).
21. Colombo JP. N-acetylglutamate synthetase (NAGS) deficiency. Adv. Exp. Med. Biol. 368, 135-143 (1994).
22. Plecko B, Erwa W, Wermuth B. Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate. Eur. J. Pediatr. 157 (12), 996-998 (1998). (Pubitemid 28559751)
23. Caldovic L, Morizono H, Gracia Panglao M et al. Cloning and expression of the human N-acetylglutamate synthase gene. Biochem. Biophys. Res. Commun. 299 (4), 581-586 (2002). (Pubitemid 36034585)
24. Häberle J, Schmidt E, Pauli S et al. Mutation analysis in patients with N-acetylglutamate synthase deficiency. Hum. Mutat. 21 (6), 593-597 (2003). (Pubitemid 36667349)
25. Schmidt E, Nuoffer JM, Häberle J et al. Identification of novel mutations of the human N-acetylglutamate synthase geneand their functional investigation by expression studies. Biochim. Biophys. Acta1740 (1), 54-59 (2005). (Pubitemid 40692698)
26. Jones S, Reed CA, Vijay S, Walter JH, Morris AA. N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia. J. Inherit. Metab. Dis.31 (Suppl. 2), S219-S222 (2008).
27. Schwahn BC, Pieterse L, Bisset WM, Galloway PG, Robinson PH. Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia. Eur. J. Pediatr. 169 (1), 133-134 (2010).
28. Tuchman M, Caldovic L, Daikhin Y et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr. Res. 64 (2), 213-217 (2008).
29. Gebhardt B, Vlaho S, Fischer D, Sewell A, Böhles H. N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria. Mol. Genet. Metab. 79 (4), 303-304 (2003). (Pubitemid 37013540)
30. Kasapkara CS, Ezgu FS, Okur I, Tumer L, Biberoglu G, Hasanoglu A. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur. J. Pediatr. 170 (6), 799-801 (2011).
31. Aires CC, van Cruchten A, Ijlst L et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J. Hepatol. 55 (2), 426-434 (2011).
32. Summar M. Current strategies for the management of neonatal urea cycle disorders. J. Pediatr. 138 (1 Suppl.), S30-S39 (2001). (Pubitemid 32099501)
33. Summar M, Tuchman M. Proceedings of a consensus conference for the management of patients with urea cycle disorders. J. Pediatr. 138 (1 Suppl.), S6-S10 (2001). (Pubitemid 32099498)
34. Häberle J, Boddaert N, Burlina A et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J. Rare Dis. (2012) (In Press).
35. Bachmann C. Hyperammonaemia: review of current treatment strategies. In: Pathophysiology and Management of Hyperammonemia. Bachmann C, Häberle J, Leonard JV (Eds). SPS Publications, Heilbronn, Germany, 157-173 (2006).
36. Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. J. Inherit. Metab. Dis. 21 (Suppl. 1), 101-111 (1998).
37. Leonard JV, Morris AA. Urea cycle disorders. Semin. Neonatol. 7 (1), 27-35 (2002). (Pubitemid 34742217)
38. Nassogne MC, Héron B, Touati G, Rabier D, Saudubray JM. Urea cycle defects: management and outcome. J. Inherit. Metab. Dis. 28 (3), 407-414 (2005). (Pubitemid 40723874)
39. Bachmann C, Colombo JP, Jaggi K. N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment. Adv. Exp. Med. Biol. 153, 39-45 (1982).
40. Guffon N, Vianey-Saban C, Bourgeois J, Rabier D, Colombo JP, Guibaud P. A new neonatal case of N-acetylglutamate synthase deficiency treated by carbamylglutamate. J. Inherit. Metab. Dis. 18 (1), 61-65 (1995).
41. Morris AA, Richmond SW, Oddie SJ, Pourfarzam M, Worthington V, Leonard JV. N-acetylglutamate synthetase deficiency: favourable experience with carbamylglutamate. J. Inherit. Metab. Dis. 21 (8), 867-868 (1998). (Pubitemid 28558684)
42. Saheki T, Ohkubo T, Katsunuma T. Regulation of urea synthesis in rat liver. Increase in the concentrations of ornithine and acetylglutamate in rat liver in response to urea synthesis stimulated by the injection of an ammonium salt. J. Biochem. 84 (6), 1423-1430 (1978).
43. Gessler P, Buchal P, Schwenk HU, Wermuth B. Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur. J. Pediatr. 169 (2), 197-199 (2010).
44. Bélanger-Quintana A, Martínez-Pardo M, García MJ et al. Hyperammonaemia as a cause of psychosis in an adolescent. Eur. J. Pediatr. 162 (11), 773-775 (2003). (Pubitemid 37410025)
45. Caldovic L, Ah Mew N, Shi D, Morizono H, Yudkoff M, Tuchman M. N-acetylglutamate synthase: structure, function and defects. Mol. Genet. Metab. 100 (Suppl. 1), S13-S19 (2010).
46. Häussinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem. J. 267 (2), 281-290 (1990). (Pubitemid 20136054)
47. Häussinger D. Liver glutamine metabolism. JPEN. J. Parenter. Enteral Nutr. 14 (4 Suppl.), 56S-62S (1990).
48. Metzenberg RL, Marshall M, Cohen PP. Purification of carbamyl phosphate synthetase from frog liver. J. Biol. Chem. 233 (1), 102-105 (1958).
49. Daniotti M, la Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int. J. Gen. Med. 4, 21-28 (2011).
50. Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics 126 (1), e208-e214 (2010).
51. Filippi L, Gozzini E, Fiorini P, Malvagia S, la Marca G, Donati MA. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. Neonatology 97 (3), 286-290 (2010).
52. Gebhardt B, Dittrich S, Parbel S, Vlaho S, Matsika O, Bohles H. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J. Inherit. Metab. Dis. 28 (2), 241-244 (2005). (Pubitemid 40723892)
53. Coude FX, Sweetman L, Nyhan WL. Inhibition by propionyl-coenzyme A of N-acetylglutamate synthetase in rat liver mitochondria. A possible explanation for hyperammonemia in propionic and methylmalonic acidemia. J. Clin. Invest. 64 (6), 1544-1551 (1979). (Pubitemid 10181294)
54. Meijer AJ, Van Woerkom GM, Wanders RJ, Lof C. Transport of N-acetylglutamate in rat-liver mitochondria. Eur. J. Biochem. 124 (2), 325-330 (1982).
55. Rubio V, Grisolia S. Human carbamoylphosphate synthetase I. Enzyme 26 (5), 233-239 (1981). (Pubitemid 12199639)
56. Hall LM, Metzenberg RL, Cohen PP. Isolation and characterization of a naturally occurring cofactor of carbamyl phosphatebiosynthesis. J. Biol. Chem. 230 (2), 1013-1021 (1958).
57. Kim S, Paik WK, Cohen PP. Ammonia intoxication in rats: protection by N-carbamoyl-l-glutamate plus l-arginine. Proc. Natl Acad. Sci. USA 69 (12), 3530-3533 (1972).
58. O'Connor JE, Jordá A, Grisolía S. Acute and chronic effects of carbamyl glutamate on blood urea and ammonia. Eur. J. Pediatr. 143 (3), 196-197 (1985). (Pubitemid 15130700)
59. Grau E, Felipo V, Miñana MD, Grisolía S. Treatment of hyperammonemia with carbamylglutamate in rats. Hepatology 15 (3), 446-448 (1992).
60. Hinnie J, Colombo JP, Wermuth B, Dryburgh FJ. N-acetylglutamate synthetase deficiency responding to carbamylglutamate. J. Inherit. Metab. Dis. 20 (6), 839-840 (1997). (Pubitemid 27501026)
61. Caldovic L, Morizono H, Daikhin Y et al. Restoration of ureagenesis in N-acetylglutamate synthase deficiency byN-carbamylglutamate. J. Pediatr. 145 (4), 552-554 (2004). (Pubitemid 39345996)
62. Guffon N, Gessler P, Galloway P et al. Treatment of NAGS deficiency: retrospective data on 23 patients treated with carglumic acid over 16 years (abstract). Mol. Genet. Metab. 102 (3), 286-287 (2011).
63. Guffon N, Schiff M, Cheillan D, Wermuth B, Häberle J, Vianey-Saban C. Neonatal hyperammonemia: the N-carbamoyl-lglutamic acid test. J. Pediatr. 147 (2), 260-262 (2005). (Pubitemid 41207845)
64. Ah Mew N, Payan I, Daikhin Y et al. Effects of a single dose of Ncarbamylglutamate on the rate of ureagenesis. Mol. Genet. Metab. 98 (4), 325-330 (2009).
65. Lévesque S, Karalis A, Lambert M, Russell L. Outcome of propionic acidemia treated at presentation with N-carbamylglutamate (abstract). Mol. Genet. Metab. 99, 203 (2010).
66. Levrat V, Forest I, Fouilhoux A, Acquaviva C, Vianey-Saban C, Guffon N. Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia? Orphanet J. Rare Dis. 3, 2 (2008).
67. Valayannopoulos V, Geb S, Chakrapani A et al. Carglumic acid (NCG) as treatment of hyperammonemia episodes in organic acidemias/acidurias (OAS): a retrospective observational study in patients from Europe and Turkey (abstract). J. Inherit. Metab. Dis. 34, S146 (2011).
68. Ah Mew N, Daikhin E, Payan I et al. N-carbamylglutamate increases ureagenesis in patients with CPSI deficiency (abstract). Mol. Genet. Metab. 99, 207 (2010).
69. Pekkala S, Martínez AI, Barcelona B et al. Structural insight on the control of urea synthesis: identification of the binding site for N-acetyl-l-glutamate, the essential allosteric activator of mitochondrial carbamoyl phosphate synthetase. Biochem. J. 424 (2), 211-220 (2009).
70. Pekkala S, Martínez AI, Barcelona B et al. Understanding carbamoyl-phosphate synthetase I (CPS1) deficiency by using expression studies and structure-based analysis. Hum. Mutat. 31 (7), 801-808 (2010).
71. Nissim I, Horyn O, Nissim I et al. Down-regulation of hepatic urea synthesis by oxypurines: xanthine and uric acid inhibit N-acetylglutamate synthase. J. Biol. Chem. 286 (25), 22055-22068 (2011).
72. Leonard JV, Richmond S. Pricing of orphan drugs. Lancet 373 (9662), 462 (2009).
73. Häberle J. Diagnosis and treatment of urea cycle disorders. J. Pediatr. Sci. 3, e65-e74 (2010).